Results 161 to 170 of about 2,169 (197)
Some of the next articles are maybe not open access.

Clinical Application of Risdiplam in 5q Spinal Muscular Atrophy: A Narrative Review

British Journal of Hospital Medicine
5q spinal muscular atrophy (SMA) is caused by mutations in the survival motor neuron (SMN) gene located on chromosome 5, leading to insufficient SMN protein levels. Risdiplam is an RNA splicing modifier that modifies pre-mRNA splicing of the SMN2 gene, thereby promoting the production of functional survival motor neuron protein (SMN-fl).
Tong, Zhao   +4 more
openaire   +2 more sources

Risdiplam bei SMA zugelassen

NeuroTransmitter, 2021
openaire   +1 more source

Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls

New England Journal of Medicine, 2021
Riccardo Masson   +2 more
exaly  

Zulassungserweiterung für Risdiplam

DNP – Die Neurologie & Psychiatrie, 2023
openaire   +1 more source

Orale Therapie der SMA mit Spleißmodulator Risdiplam

DNP - Der Neurologe & Psychiater, 2022
Svenja Brakemeier, Tim Hagenacker
openaire   +1 more source

Risdiplam von Geburt an

InFo Neurologie + Psychiatrie, 2023
openaire   +1 more source

P.113 Safety update: Risdiplam clinical trial development program

Neuromuscular Disorders, 2022
Chiriboga, Claudia A.   +19 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy